Home  |  Contact

UniProtKB/Swiss-Prot P38398: Variant p.Ser1651Phe

Breast cancer type 1 susceptibility protein
Gene: BRCA1
Variant information

Variant position:  1651
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  US
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Serine (S) to Phenylalanine (F) at position 1651 (S1651F, p.Ser1651Phe).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from small size and polar (S) to large size and aromatic (F)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In BC; unknown pathological significance.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  1651
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1863
The length of the canonical sequence.

Location on the sequence:   SVSREKPELTASTERVNKRM  S MVVSGLTPEEFMLVYKFARK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARK

Gorilla                       SVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARK

                              SVGIEKPEVISSTRGVNKRISMVASGLTPKEFMLVHKFARK

Rhesus macaque                SVSRENPKLTASTERVNKRMSLVVSGLTPEEFMLVYKFARR

Chimpanzee                    SVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARK

Mouse                         IVSKIKPELTSSEERADRDISMVVSGLTPKEVMTVQKFAEK

Rat                           IVSKIKPEVTSPKERAERDISMVVSGLTPKEVMIVQKFAEK

Bovine                        SMSKEKPEVISSTERSKKRLSMVASGLTPKELMLVQKFARK

Caenorhabditis elegans        ------------------------------------RFAED

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1863 Breast cancer type 1 susceptibility protein
Domain 1642 – 1736 BRCT 1
Alternative sequence 64 – 1863 Missing. In isoform 2.
Mutagenesis 1655 – 1655 S -> A. Abolishes interaction with BRIP1.
Mutagenesis 1656 – 1656 G -> D. No effect on affinity for a BRIP1 phosphopeptide.
Mutagenesis 1662 – 1662 F -> S. Does not abolish ABRAXAS1 binding, but abolishes formation of a heterotetramer with ABRAXAS1.
Mutagenesis 1663 – 1663 M -> K. Does not abolish ABRAXAS1 binding, but abolishes formation of a heterotetramer with ABRAXAS1.
Mutagenesis 1666 – 1666 Y -> A. Does not abolish ABRAXAS1 binding, but impairs formation of a heterotetramer with ABRAXAS1.
Mutagenesis 1670 – 1670 R -> E. Impairs formation of a heterotetramer with ABRAXAS1.
Mutagenesis 1671 – 1671 K -> E. Impairs formation of a heterotetramer with ABRAXAS1.
Beta strand 1651 – 1656


Literature citations

A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P.; van der Gulden H.; van der Heijden I.; Drost R.; Klijn C.N.; Prasetyanti P.; Pieterse M.; Wientjens E.; Seibler J.; Hogervorst F.B.; Jonkers J.;
Cancer Discov. 3:1142-1155(2013)
Cited for: CHARACTERIZATION OF VARIANTS BC PHE-4; THR-18; GLN-45; GLY-61; GLY-64; TYR-67; LYS-132; HIS-142; PHE-147; PRO-165; TRP-170; TYR-186; ILE-191; MET-231; VAL-245; VAL-246; LEU-271; PHE-668; ASN-695; LEU-798; TYR-810; LYS-826; GLN-841; HIS-856; ASN-1101; ASN-1140; GLY-1140; LYS-1214; LYS-1236; SER-1267; VAL-1282; SER-1297 DEL; ARG-1301; LYS-1346; ILE-1378; VAL-1400; PRO-1407; THR-1411; GLY-1443; GLY-1448; CYS-1486; MET-1534; PRO-1589; THR-1628; PRO-1651; PHE-1651; PHE-1655; ARG-1686; GLN-1686; VAL-1688 DEL; ILE-1691; TRP-1699; GLN-1699; GLU-1706; ALA-1706; GLU-1708; CYS-1718; ALA-1720; LYS-1735; ALA-1736; GLY-1739; VAL-1739; GLN-1746; THR-1753; PRO-1764; SER-1767; VAL-1770; CYS-1782; THR-1789; ASP-1794; ASP-1804; ARG-1812; ARG-1837 AND LEU-1862; VARIANTS CYS-105; CYS-866; ALA-1060; LYS-1250 AND ILE-1652;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.